Workshop Overview Leadership Hotel and Travel Registration Program Agenda
The Cancer Immune Responsiveness Task Force will host a two-day workshop on May 14-15 that will bring together stakeholders to discuss topics including:
This workshop will lbe held back-to-back with a two-day workshop from the Biomarkers Task Force in May 2018. Participants are welcome to attend all four days of presentations and break-out session discussions. Click here for more information about the Immune Responsiveness Workshop.
Josue Samayoa, PhDAbbvie Biotherapeutics Corp.
Stefanie Spranger, PhDKoch Institute for Integrative Cancer Research at MIT
Please join Bob Ferris, Ezra Cohen and me plus a stellar group of faculty for the 3rd New Horizons in Immunotherapy for Head and Neck Cancer , June 15-16, 2018 in Pittsburgh, PA! ------------------------------ R. Bryan Bell MD, DDS, FACS Medical ...
A specificarticle reviewed the literature on efficacy and safety of CTLA-4 and PD-1-blocking antibodies in preexisting autoimmune disorder patients.This Paper suggests, on the basis of evidence, that ipilimumab and anti-PD-1 immunotheray agents can be ...
From Parp inhibitors to anti-PD-1 therapies, here we present an overview of the biggest news stories from 2018 ASCO-SITC Clinical Immuno-Oncology Symposium (January 25–27; CA, USA).
Study suggests anti-PD-1 therapy could be enhanced ...
Hi Hegel I came across to the following:Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations Jun Gong, Alexander Chehrazi-Raffle, Srikanth Reddi and Ravi ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com